Abstract: A biosensor for use in detecting the presence of diseases, the biosensor comprising a detector for detecting a presence of at least one marker indicative of a specific disease. A method of determining efficacy of a pharmaceutical for treating a disease or staging disease by administering a pharmaceutical to a sample containing markers for a disease, detecting the amount of at least one marker of the disease in the sample, and analyzing the amount of the marker in the sample, whereby the amount of marker correlates to pharmaceutical efficacy or disease stage. Markers for gynecological disease. An immune-imaging agent comprising labeled antibodies, whereby the labeled antibodies are isolated and reactive to proteins overexpressed in vivo. Informatics software for analyzing the arrays, the software including analyzing means for analyzing the arrays.

Abstract: An object of the present invention is to provide a method of reducing interference to a measurement system from water-soluble silicone and/or surfactant contaminating the measurement system in a latex agglutination immunoassay. The execution of a latex immunoagglutination reaction in the presence of a silicone compound can reduce the interference to the measurement system from a component derived from a micro blood-collection tube (water-soluble silicone) and/or surfactant mixed from outside of the measurement system.

Abstract: A method for species-independent measurement of complement (C) activation in animals. The method comprises taking samples in the range of 3-100 microliter of anticoagulated blood, plasma or serum of an animal (specimen), mixing the specimen with a specificity converting protein matrix (SCM), mixing to the specimen/SCM mixture an activator of the C system (Act), incubating the specimen/SCM/Act mixture at a temperature between 36° C. to 38° C. for a time of 5-120 min and determining the production of one or more human proteins by ELISA or other analytical methods.

Abstract: Described herein are new recognition elements (antibodies or functional fragments thereof) that effectively bind to trinitrotoluene (TNT). Also disclosed is a single chain fragment recognition element.

Abstract: The present invention relates to the chromatographic isolation of a target cell or another complex biological material, in particular by column chromatography such as affinity chromatography or gel permeation chromatography. The invention employs a receptor binding reagent that binds to a receptor molecule that is located on the surface of a target cell. The invention in general provides novel methods for the traceless isolation of biologic materials such as cells, cell organelles, viruses and the like. The invention also relates to an apparatus for the isolation of cells and other complex biological materials.

Abstract: The present disclosure provides methods and compositions for separating polypeptide glycoforms using a medium that includes an Fc receptor. In certain embodiments, a medium includes an Fc receptor which comprises an extracellular portion of an Fc gamma RIII receptor.

Abstract: The disclosure relates to methods for measuring levels of 25(OH)vitamin D (25OHD) in a mammalian fluid sample. The disclosure further relates to kits for measuring levels of 25(OH)vitamin D (25OHD) in a mammalian fluid.

Abstract: In a known method of measuring a target substance, comprising: providing a sample solution containing the target substance, a first reaction solution, and a second reaction solution; sequentially aspirating the sample solution and the first reaction solution, using a measuring apparatus equipped with a dispensing unit, into the dispensing unit; discharging them at a time from the dispensing unit, to bring them into contact with the second reaction solution, and to form a complex of the target substance and a first partner which is contained in at least one of the first reaction solution or the second reaction solution and reacts specifically with the target substance; and analyzing the resulting complex, an improved method capable of inhibiting a reaction which adversely affects measurement results is provided.

Abstract: The present invention relates to the identification of a novel biomarker for cardiac ischemia: nitrated cardiac troponin I. The present invention also provides methods for the identification and use of a nitrated cardiac troponin as a biomarker for the diagnosis, prognosis and treatment management of myocardial ischemia, with and without necrosis of heart muscle. Diagnosis and prognosis is conducted by determining the amount of nitrated cardiac troponin I in serum samples of subjects and the ratio of nitrated cardiac troponin I to non-nitrated cardiac troponin I in serum samples of subjects. This biomarker can be detected by immunoassay techniques and tandem mass spectrometry. The present invention further relates to peptides, antibodies, compositions, methods, techniques, tests and kits for the identification and quantification of nitrated cardiac troponin I in samples of subjects.

Abstract: Disclosed is an antibody which binds to aripiprazole, which can be used to detect aripiprazole in a sample such as in a competitive immunoassay method. The antibody can be used in a lateral flow assay device for point-of-care detection of aripiprazole, including multiplex detection of aripiprazole, olanzapine, quetiapine, and risperidone in a single lateral flow assay device.

Abstract: The invention provides methods and systems for detecting a biomarker in a synovial fluid wherein the system also includes a control to ensure that the test sample is indeed synovial fluid. The biomarkers and the control for synovial fluid can be identified using proteomic methods, including but not limited to antibody based methods, such as an enzyme-linked immunosorbant assay (ELISA), a radioimmunoassay (RIA), or a lateral flow immunoassay.

Abstract: The invention provides a two-step chromatography process for small and large-scale purification of proteins, specifically monoclonal antibodies, using only four buffer solutions made from a mother solution.

Abstract: A method for predicting risk of gestational diabetes mellitus (GDM) in a pregnant individual includes measuring one or more biochemical markers in a blood sample obtained from the pregnant individual to determine one or more biomarker levels, where the one or more measured biochemical markers includes at least one of PAI-2 and sTNFR1, identifying, for each of the one or more measured biochemical markers, a difference between the measured biomarker level and a corresponding predetermined control level, and, responsive to the identifying, determining a prediction corresponding to a relative risk of the pregnant individual having or developing GDM.

Abstract: Methods and kits for reducing non-specific binding in an immunoassay for PIVKA-II in a test sample are described, in which the test sample is reacted with an anti-prothrombin antibody in the presence of one or more of the following additives: skim milk, saponin, CaCl2, MgCl2, and a sulfobetaine zwitterionic detergent.

Abstract: The present invention provides simple and inexpensive assays for the detection of virtually any analyte in any sample that is in liquid form or that can be solubilized. The assays utilize the fluid dynamics of drop evaporation whereby soluble materials, including analytes and particles binding thereto, are drawn to the center of the drop by Marangoni flow and ultimately form a concentrated residual spot. The presence or absence of certain reagents can then be detected through a number of different approaches.

Abstract: A detection device for detecting analytes in liquid specimen is provided. The detection device comprises: a specimen chamber for collecting or storing a liquid specimen; a detecting chamber for containing a detecting element; and a through hole for transferring the liquid specimen between the specimen chamber and the detecting chamber. The through hole can be opened or self-sealed. The sealing or opening of the through hole controls whether or not the liquid specimen in the specimen chamber enters the detecting chamber via the through hole. Furthermore, a detection method is provided.

Abstract: The present application relates to a method of assaying ubiquitination in a sample by combining ubiquitin together with a substrate in a sample containing UBE1, UbcH3, Skp2-isoform 1, Skp1, Cull, Rbx1, Cks1, CDK2 and Cyclin E1 under conditions suitable for ubiquitination to take place, exposing the sample to a labelled binding partner which is specific for the ubiquitin, and measuring the amount of ubiquitin bound to the substrate.

Abstract: Methods are disclosed for non-invasively obtaining fetal cells from a pregnant female. The methods include placing an absorbent medium in an interlabial or intravaginal space or adjacent to the perineum at the vaginal opening of the pregnant female, and collecting vaginal fluid comprising cells in the absorbent medium while the absorbent medium is interlabial or intravaginal space or adjacent to the perineum at the vaginal opening. The absorbent medium is removed and cells are isolated from the absorbent medium to obtain the fetal cells. The fetal cells can be, for example, somatic cells, embroyic stem cells, fetal stem cells or trophoblast cells.

Abstract: The present invention related to a method of assaying ubiquitination in a sample by combining ubiquitin and two or more of E1, E2, E3 and a substrate protein in a sample under conditions suitable for ubiquitination to take place, exposing the sample with a labelled binding partner which is specific for the ubiquitin and measuring the amount of labelled ubiquitin bound to any one of the components in the sample, wherein one or more of the components in the sample comprises an immobilization tag which facilitates its immobilization onto a solid surface.

Abstract: An electrochemiluminescence immunoassay method is disclosed and uses a full reaction of a Ru(bpy) marked protein-primary antibody, a biotinylated protein-secondary antibody to be tested, and a sample to be tested; addition of a Streptavidin-coated magnetic particle to form a complex comprising an antigen, an antibody, and a magnetic particle; adsorption to an electrode surface by the magnetic particle; addition of a dibutyl ethanolamine solution; and testing by an electrochemical method. Also disclosed is a corresponding electrochemiluminescence immunoassay detection kit.